First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Titel:
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Auteur:
Descourt, Renaud Greillier, Laurent Perol, Maurice Ricordel, Charles Auliac, Jean-Bernard Falchero, Lionel Gervais, Radj Veillon, Rémi Vieillot, Sabine Guisier, Florian Marcq, Marie Justeau, Grégoire Bigay-Game, Laurence Bernardi, Marie Fournel, Pierre Doubre, Hélène Pinsolle, Julian Amrane, Karim Chouaïd, Christos Decroisette, Chantal